Current studies such as the NEOADAURA trial, which evaluates the use of neoadjuvant osimertinib in patients with resectable NSCLC prior to surgery,13 and the LAURA trial, which is investigating the use of adjuvant osimertinib following ChRT in patients with unresectable LA-NSCLC,14 may further improve outcomes in patients with EGFR mutated tumors treated with ChRT. This evidence concerns the gene EGFR and non-small cell lung carcinoma.